New Targets for Migraine Therapy

Current Treatment Options in Neurology

Volumn 16, Issue 11, 2014, Pages

  Tso, Amy R ^a   Goadsby, Peter J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Acute; Headache; Migraine; Preventive; Review; Treatment

Indexed keywords

ADX 10059; ALD 403; AMG 334; AMILORIDE; ANTIMIGRAINE AGENT; BGG 492; BI 44370TA; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; ELETRIPTAN; FILOREXANT; FLUNARIZINE; GLUTAMATE RECEPTOR ANTAGONIST; LASMIDITAN; LY 2951742; MIDAZOLAM; MK 3207; NITRIC OXIDE SYNTHASE INHIBITOR; NXN 188; RIMEGEPANT; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; SEROTONIN AGONIST; SUMATRIPTAN; TELCAGEPANT; TEZAMPANEL; TRIPTAN DERIVATIVE; UBROGEPANT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST;

ANALGESIA; HUMAN; MIGRAINE; MULTICENTER STUDY (TOPIC); NERVE STIMULATION; NEUROMODULATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE PULSE TRANSCRANIAL MAGNETIC STIMULATION; SPHENOPALATINE GANGLION STIMULATION; SUPRAORBITAL NEUROSTIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION;

EID: 84919941467     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-014-0318-1     Document Type: Review

References (72)

1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–96. doi:10.1016/S0140-6736(12)61729-2.
2. Gowers W. A manual of diseases of the nervous system. 3rd ed. Philadelphia: P. Blakiston, Son & Co; 1899.
3. Liveing E. On megrim, sick-headache, and some allied disorders. A contribution to the pathology of nerve-storms. London: Arts & Boeve Nijmegen; 1873.
4. Ray BS, Wolff HG. Experimental studies on headache: pain-sensitive structures of the head and their significance in headache. Arch Surg. 1940;41:813–56.
5. Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch. Neurol. Psychiatr. 1938:737-63.
6. Feniuk W, Humphrey PP, Perren MJ, et al. Rationale for the use of 5-HT1-like agonists in the treatment of migraine. J Neurol. 1991;238 Suppl 1:S57–61.
7. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol. 1981;9(4):344–52. doi:10.1002/ana.410090406.
8. Olesen J, Friberg L, Olsen TS, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol. 1990;28(6):791–8. doi:10.1002/ana.410280610.
9. Amin FM, Asghar MS, Hougaard A, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol. 2013;12(5):454–61. doi:10.1016/S1474-4422(13)70067-X.
10. Afridi SK, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005;128(Pt 4):932–9.
11. Maniyar FH, Sprenger T, Monteith T, et al. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 2014;137(Pt 1):232–41. doi:10.1093/brain/awt320. PET imaging study showing that changes in brain activity begin in the premonitory phase well before the onset of pain.
12. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011;12(10):570–84. doi:10.1038/nrn3057.
13. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia Int J Headache. 2010;30(7):793–803. doi:10.1177/0333102410364676.
14. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia Int J Headache. 2010;30(7):804–14. doi:10.1177/0333102410364677.
15. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia Int J Headache. 2002;22(8):633–58.
16. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010;9(3):285–98. doi:10.1016/S1474-4422(10)70005-3.
17. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193–6. doi:10.1002/ana.410230214.
18. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–7. doi:10.1002/ana.410280213.
19. Cernuda-Morollon E, Larrosa D, Ramon C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81(14):1191–6. doi:10.1212/WNL.0b013e3182a6cb72.
20. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia Int J Headache. 2002;22(1):54–61.
21. Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia Int J Headache. 2010;30(10):1179–86. doi:10.1177/0333102410368444.
22. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372(9656):2115–23. doi:10.1016/S0140-6736(08)61626-8.
23. Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73(12):970–7. doi:10.1212/WNL.0b013e3181b87942.
24. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia Int J Headache. 2011;31(6):712–22. doi:10.1177/0333102411398399.
25. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–10. doi:10.1056/NEJMoa030505.
26. Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia Int J Headache. 2014;34(2):114–25. doi:10.1177/0333102413500727. Recent trial showing a CGRP antagonist has efficacy comparable to sumatriptan for acute treatment of migraine.
27. Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia Int J Headache. 2011;31(5):573–84. doi:10.1177/0333102410388435.
28. Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014. doi:10.1212/WNL.0000000000000771.
29. Leone M, Grazzi L, La Mantia L, et al. Flunarizine in migraine: a minireview. Headache. 1991;31(6):388–91.
30. Soyka D, Taneri Z, Oestreich W, et al. Flunarizine i.v. in the acute treatment of the migraine attack. A double-blind placebo-controlled study. Cephalalgia Int J Headache. 1988;8 Suppl 8:35–40.
31. Goadsby PJ. Migraine: emerging treatment options for preventive and acute attack therapy. Expert Opin Emerg Drugs. 2006;11(3):419–27. doi:10.1517/14728214.11.3.419.
32. Goadsby PJ, Dodick D, Silberstein S, et al. Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP peptide antibody in the prevention of frequent episodic migraine. Headache. 2014;54:in press.
33. de Hoon J, Montieth D, Vermeersch S, et al. Safety, pharmacokinetics, and pharmacodynamics of LY2951742: a monoclonal antibody targeting CGRP. Cephalalgia Int J Headache. 2013;33(8 suppl):247–8.
34. Dodick D, Goadsby PJ, Spierings EL, et al. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study. Headache. 2014;54:in press.
35. Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia Int J Headache. 2013;34(7):483–92. doi:10.1177/0333102413517775.
36. Headache Classification Committee of the International Headache S. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia Int J Headache. 2013;33(9):629–808. doi:10.1177/0333102413485658.
37. Shi L, Rao S, King C, et al. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor. Headache. 2014; 54:in press.
38. Goldstein DJ, Roon KI, Offen WW, et al. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001;358(9289):1230–4.
39. Farkkila M, Diener HC, Geraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405–13. doi:10.1016/S1474-4422(12)70047-9.
40. Ziemann AE, Schnizler MK, Albert GW, et al. Seizure termination by acidosis depends on ASIC1a. Nat Neurosci. 2008;11(7):816–22. doi:10.1038/nn.2132.
41. Friese MA, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med. 2007;13(12):1483–9. doi:10.1038/nm1668.
42. Holland PR, Akerman S, Andreou AP, et al. Acid-sensing ion channel 1: a novel therapeutic target for migraine with aura. Ann Neurol. 2012;72(4):559–63. doi:10.1002/ana.23653.
43. Diochot S, Baron A, Salinas M, et al. Black mamba venom peptides target acid-sensing ion channels to abolish pain. Nature. 2012;490(7421):552–5. doi:10.1038/nature11494.
44. Ma QP. Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport. 2001;12(8):1589–91.
45. Andreou AP, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opin Investig Drugs. 2009;18(6):789–803. doi:10.1517/13543780902913792.
46. Ramadan NM. The link between glutamate and migraine. CNS Spectr. 2003;8(6):446–9.
47. Sang CN, Ramadan NM, Wallihan RG, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia Int J Headache. 2004;24(7):596–602. doi:10.1111/j.1468-2982.2004.00723.x.
48. Marin JC, Goadsby PJ. Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine? Expert Opin Investig Drugs. 2010;19(4):555–61. doi:10.1517/13543781003691832.
49. Gomez-Mancilla B, Brand R, Jurgens TP, et al. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia Int J Headache. 2014;34(2):103–13. doi:10.1177/0333102413499648.
50. Afridi SK, Giffin NJ, Kaube H, et al. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology. 2013;80(7):642–7. doi:10.1212/WNL.0b013e3182824e66.
51. Wei EP, Moskowitz MA, Boccalini P, et al. Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles. Circ Res. 1992;70(6):1313–9.
52. Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain. 2004;110(3):675–80. doi:10.1016/j.pain.2004.05.007.
53. Palmer J, Guillard F, Laurijssens B, et al. A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia Int J Headache. 2009;29:124.
54. Hoivik HO, Laurijssens BE, Harnisch LO, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia Int J Headache. 2010;30(12):1458–67. doi:10.1177/0333102410370875.
55. Medve R, Andrews J. Effects of fixed dose combination of nNOS inhibition and 5HT agonism on progression of migraine with and without aura. Cephalalgia Int J Headache. 2009;29:126.
56. Hou M, Uddman R, Tajti J, et al. Capsaicin receptor immunoreactivity in the human trigeminal ganglion. Neurosci Lett. 2002;330(3):223–6.
57. Story GM, Peier AM, Reeve AJ, et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell. 2003;112(6):819–29.
58. Kunkler PE, Ballard CJ, Oxford GS, et al. TRPA1 receptors mediate environmental irritant-induced meningeal vasodilatation. Pain. 2011;152(1):38–44. doi:10.1016/j.pain.2010.08.021.
59. Anttila V, Stefansson H, Kallela M, et al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet. 2010;42(10):869–73.
60. Anttila V, Winsvold BS, Gormley P, et al. Genome-wide meta-analysis identifies new susceptibility loci for migraine. Nat Genet. 2013;45(8):912–7. doi:10.1038/ng.2676. Meta-analysis of 29 genome-wide association studies identifying susceptibility loci for migraine.
61. Chasman DI, Schurks M, Anttila V, et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet. 2011;43(7):695–8. doi:10.1038/ng.856.
62. Freilinger T, Anttila V, de Vries B, et al. Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat Genet. 2012;44(7):777–82. doi:10.1038/ng.2307.
63. Summ O, Holland PR, Akerman S, et al. TRPV1 receptor blockade is ineffective in different in vivo models of migraine. Cephalalgia Int J Headache. 2011;31(2):172–80. doi:10.1177/0333102410375626.
64. Rami HK, Thompson M, Stemp G, et al. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett. 2006;16(12):3287–91. doi:10.1016/j.bmcl.2006.03.030.
65. Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia Int J Headache. 2012;32(16):1165–79. doi:10.1177/0333102412462642.
66. Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80(8):697–704. doi:10.1212/WNL.0b013e3182825055.
67. Magis D, Sava S, D'Elia TS, et al. Safety and patients' satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly(R) device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013;14:95. doi:10.1186/1129-2377-14-95.
68. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9(4):373–80. doi:10.1016/S1474-4422(10)70054-5.
69. Bhola RLS, Giffin N, Elrington G, et al. Update of the UK post market pilot programme with Single Pulse Transcranial Magnetic Stimulation (sTMS) for acute treatment of migraine. Cephalalgia Int J Headache. 2013;33:973.
70. Goadsby P, Grosberg B, Mauskop A, et al. Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia Int J Headache. 2014. doi:10.1177/0333102414524494.
71. Magis D, Gerard P, Schoenen J. Transcutaneous Vagus Nerve Stimulation (tVNS) for headache prophylaxis: initial experience. The European Headache and Migraine Trust International Congress; 2012; London, UK.
72. Tepper SJ, Rezai A, Narouze S, et al. Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache. 2009;49(7):983–9. doi:10.1111/j.1526-4610.2009.01451.x.